tbuckley/cabot-search huggingface dataset:
Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
Authors: Francesca Maria Gay, Delia Rota Scalabrini, Angelo Belotti, Massimo Offidani, Maria Teresa Petrucci, Fabrizio Esma, Angelo D. Palmas, Tommaso Caravita, Mariella Grasso, Sara Aquino, Barbara Gamberi, Renato Zambello, Antonio Ledda, Vittorio Montefusco, Paola Omedè, Monica Galli, Michele Cavo, Antonio Palumbo, Pellegrino Musto, Mario Boccadoro
Journal: Journal of Clinical Oncology (2017)

8003 Background: Phase I/II studies showed the safety and efficacy of KRd and KCd in NDMM pts (Jakubowiak Blood 2012, Bringhen Blood 2014). Methods: NDMM pts ≤65 yrs were randomized (1:1:1; stratification ISS and age) to: 4 28-day KCd cycles (carfilzomib:20/36 mg/m 2 IV d 1,2,8,9,15,16; cyclophosphamide 300 mg/m 2 d 1,8,15; dexamethasone:20 mg d 1,2,8,9,15,16) followed by MEL200-ASCT and consolidation with 4 KCd cycles; or 4 28-day KRd cycles (carfilzomib and dexamethasone as above; lenalidomide:25 mg d 1-21) followed by MEL200-ASCT and 4 KRd cycles; or 12 KRd cycles. After the 4 th induction cycle, all pts received Cyclophosphamide 2 g/m 2 , followed by PBSC collection. We report results of the first planned safety interim analysis on induction and mobilization and preliminary efficacy data. We pooled the 2 KRd groups since treatment was the same until mobilization. Data cut-off was October 30, 2016. Results: 281 pts were evaluated (KCd, n=94; KRd, n=187). The most frequent grade 3-4 AEs plus SAEs in both arms were hematological (mainly neutropenia) and infections (mainly pneumonia/fever); increased AST/ALT/GGT (mainly reversible) and dermatological (rash) AEs were higher in KRd; cardiac AEs were 2% (atrial fibrillation[1%]/ischemic heart disease[1%]) in KRd vs 1% (atrial fibrillation) in KCd. In KCd, 1 pt died of infection (not treatment-related) vs 3 in the KRd (2 cardiac arrest [1 not treatment-related],1 infection not treatment-related). In the KCd vs KRd arms, 99% vs 95% (P=0.44) of pts mobilized stem cells (median number of PBSC collected:9 vs 6x10^6CD34/Kg with KCd vs KRd); 10% vs 24% (P=0.01) required Plerixafor. Rate of ≥VGPR was 61% with KCd vs 74% with KRd (P=0.05). Conclusions: Safety profile was acceptable; more pts required plerixafor in KRd. Rate of VGPR was higher with KRd. Updated data on more patients will be presented at the meeting. Clinicaltrials.gov NCT02203643. [Table: see text]
Bilious pleuritis following transpulmonary radiofrequency ablation of liver metastases
Authors: Asli Kalin, Maged Hassan, Mark Anderson, Najib Rahman
Journal: Thorax (2017)

Figure 2 Postcontrast chest CT. (A) Axial cut in the lower chest reveals right pleural effusion with evidence of air bubbles (arrows) strongly suggesting infection.Also, note the pleural enhancement (arrowheads) denoting intense inflammation.(B) Para-sagittal reconstruction clearly delineates transdiaphragmatic communication (arrow) between fluid collection inside the liver substance and the supradiaphragmatic space.
The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading
Authors: Roberta Tarallo, Giorgio Giurato, Giuseppina Bruno, Maria Ravo, Francesca Rizzo, Annamaria Salvati, Luca Ricciardi, Giovanna Marchese, Angela Cordella, Teresa Rocco, Valerio Gigantino, Biancamaria Pierri, Giovanni Cimmino, Luciano Milanesi, Concetta Ambrosino, Tuula A. Nyman, Giovanni Nassa, Alessandro Weisz
Journal: Genome biology (2017)

The RNA-binding protein Argonaute 2 (AGO2) is a key effector of RNA-silencing pathways It exerts a pivotal role in microRNA maturation and activity and can modulate chromatin remodeling, transcriptional gene regulation and RNA splicing. Estrogen receptor beta (ERβ) is endowed with oncosuppressive activities, antagonizing hormone-induced carcinogenesis and inhibiting growth and oncogenic functions in luminal-like breast cancers (BCs), where its expression correlates with a better prognosis of the disease.Applying interaction proteomics coupled to mass spectrometry to characterize nuclear factors cooperating with ERβ in gene regulation, we identify AGO2 as a novel partner of ERβ in human BC cells. ERβ-AGO2 association was confirmed in vitro and in vivo in both the nucleus and cytoplasm and is shown to be RNA-mediated. ChIP-Seq demonstrates AGO2 association with a large number of ERβ binding sites, and total and nascent RNA-Seq in ERβ + vs ERβ - cells, and before and after AGO2 knock-down in ERβ + cells, reveals a widespread involvement of this factor in ERβ-mediated regulation of gene transcription rate and RNA splicing. Moreover, isolation and sequencing by RIP-Seq of ERβ-associated long and small RNAs in the cytoplasm suggests involvement of the nuclear receptor in RISC loading, indicating that it may also be able to directly control mRNA translation efficiency and stability.These results demonstrate that AGO2 can act as a pleiotropic functional partner of ERβ, indicating that both factors are endowed with multiple roles in the control of key cellular functions.
Prevalência da infecção por HIV-2 na Europa
Authors: F Cazein, F F Hamers, J Alix, J B Brunet
Journal: Eurosurveillance (1996)

A pandemia de HIV/SIDA e sobretudo causada pelo HIV-1. Outro tipo de virus, o HIV-2, encontra-se principalmente em certos paises da Africa Ocidental (1-5). Na Europa, a maior parte dos casos de infeccao pelo HIV-2 foram descritos em individuos oriundos de Africa (6).O objectivo deste estudo foi determinar a prevalencia da infeccao por HIV-2 em paises da Europa, e compara-la com a seroprevalencia da infeccao por HIV-1 nas populacoes testadas.
Improving the patient (pt) experience through physician engagement.
Authors: William A. Dunson, Don Milligan, John W. Sweetenham, Joan Arata, John Darden, Joy Lombardi, Leslie Roberts-Freimann, Shelley Shallbetter, Jean Brown, Connie Hillier, Stephanie Bisel, Robin Phillips
Journal: Journal of Clinical Oncology (2014)

e17641 Background: At the University of Utah’s Huntsman Cancer Institute (HCI), we assess pt experience using a nationally based private survey company. Although ranking highly on the inpatient units, HCI’s outpatient clinics were at the fifth percentile nationally in 2005. Physicians were focused on academic objectives including research, teaching, clinical care, and medical outcomes. In recent years, there has been heightened interest in pt experience as a quality indicator. HCI developed novel strategies to increase physician engagement in improving pt experience. Methods: We designed interventions aimed at engaging the physicians by taking advantage of common physician traits such as being successful, competitive, scientific, and being outcomes-focused. These traits drove the interventions that were implemented including organizationally changing the traditional academic definition of success to include the patient experience, an unblinded physician ranking, and specific physician/team meetings to address what the physicians themselves had identified as clinic process problems (e.g., lack of adequate staffing, slow turnover time in the lab and radiology, and pts showing up late). Study endpoints included overall satisfaction national percentile ranking and national ranking of the question “likelihood of recommending services”. These endpoints were evaluated using a nationally based private survey company. Results: The overall satisfaction score improved from fifth percentile nationally (mean score 87.3, n=925) in 2005 to ninety-seventh percentile nationally (mean score 94.0, n= 6,950) in 2013 (see Table). ‘Likelihood of recommending services’ increased from forty-third percentile nationally (mean score 95.0, n=881) in 2005 to nintey-ninth percentile nationally (mean score 96.9, n=6,869) in 2013. Conclusions: Engaging in a process improvement process targeted at physician engagement in addition to standard pt satisfaction improvement modalities is highly successful in improving the pt experience in the outpatient clinics in an academic oncology hospital. Year National ranking Mean score n 05 5 87.3 925 06 9 88.2 1,045 07 7 87.9 1,611 08 17 89.4 1,752 09 30 90.7 4,521 10 39 91.5 4,947 11 74 92.1 5,085 12 88 93.0 5,912 13 97 94.0 6,950
Quality of life (QoL) of patients (pts) with metastatic pancreatic cancer (mPAC) initiating first-line chemotherapy (CT) in routine practice
Authors: B. Laquente, T. Macarulla, C. Bugés, M. Martín, C. García, E. Dotor, S. Merino, L. Visa, T. Martín, M. Pedraza, R. Guardeño, L. Pellín, D. Vilanova, A. García
Journal: Annals of Oncology (2017)
Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): Results from the FOXFIRE prospective randomized studies
Authors: A.M. Gray, J. Wolstenholme, F. Fusco, I. Chau, L. Dunham, S. Love, A. Roberts, J. Moschandreas, P. Virdee, V. Lewington, G. Wilson, P. Tait, N. Khan, D. Berry, A. Wotherspoon, B. Morgan, H. Wasan, G. Van Hazel, P. Gibbs, R. Sharma
Journal: Annals of Oncology (2017)
Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations
Authors: H. Kenmotsu, C.K. Imamura, T. Kawamura, T. Oyakawa, S. Omori, K. Nakashima, K. Wakuda, A. Ono, T. Taira, T. Naito, H. Murakami, N. Yamamoto, T. Takahashi, Y. Tanigawara
Journal: Annals of Oncology (2017)
Incidence and survival of secondary malignances (SM) in oropharingeal squamous cell carcinoma (OPSCC): A homogeneous single report institution
Authors: M. Napolitano, F. Bertolini, E. D'Angelo, A. Spallanzani, S. Tassi, B. Meduri, S. Bettelli, R. Depenni, A. Ghidini, F. Lohr, L. Presutti, S. Cascinu
Journal: Annals of Oncology (2017)
Real-life study of BRCA genetic screening in metastatic breast cancer
Authors: G. Meynard, C. Villanueva, A. Thiery-Vuillemin, L. Mansi, P. Montcuquet, N. Meneveau, L. Chaigneau, F. Bazan, H. Almotlak, E. Dobi, T. Nguyen Tan Hon, E. Klajer, C. Fagnoni-Legat, S. Paget-Bailly, A. Meurisse, M-A. Collonge-Rame, C. Populaire-Ventron, X. Pivot, E. Curtit
Journal: Annals of Oncology (2017)
Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex–Mediated Membranoproliferative GN
Authors: Paraskevas Iatropoulos, Erica Daina, Manuela Curreri, Rossella Piras, Elisabetta Valoti, Caterina Mele, Elena Bresin, Sara Gamba, Marta Alberti, Matteo Breno, Annalisa Perna, Serena Bettoni, Ettore Sabadini, Luisa Murer, Marina Vivarelli, Marina Noris, Giuseppe Remuzzi
Journal: Journal of the American Society of Nephrology (2017)

Membranoproliferative GN (MPGN) was recently reclassified as alternative pathway complement-mediated C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative GN (IC-MPGN). However, genetic and acquired alternative pathway abnormalities are also observed in IC-MPGN. Here, we explored the presence of distinct disease entities characterized by specific pathophysiologic mechanisms. We performed unsupervised hierarchical clustering, a data-driven statistical approach, on histologic, genetic, and clinical data and data regarding serum/plasma complement parameters from 173 patients with C3G/IC-MPGN. This approach divided patients into four clusters, indicating the existence of four different pathogenetic patterns. Specifically, this analysis separated patients with fluid-phase complement activation (clusters 1-3) who had low serum C3 levels and a high prevalence of genetic and acquired alternative pathway abnormalities from patients with solid-phase complement activation (cluster 4) who had normal or mildly altered serum C3, late disease onset, and poor renal survival. In patients with fluid-phase complement activation, those in clusters 1 and 2 had massive activation of the alternative pathway, including activation of the terminal pathway, and the highest prevalence of subendothelial deposits, but those in cluster 2 had additional activation of the classic pathway and the highest prevalence of nephrotic syndrome at disease onset. Patients in cluster 3 had prevalent activation of C3 convertase and highly electron-dense intramembranous deposits. In addition, we provide a simple algorithm to assign patients with C3G/IC-MPGN to specific clusters. These distinct clusters may facilitate clarification of disease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment.
Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT)
Authors: C. Leduc, E. Pencreach, J-P. Merlio, P-P. Bringuier, F. de Fraipont, F. Escande, A. Lemoine, O. L'Houcine, H. Blons, M. Denis, P. Hofman, R. Lacave, S. Melaabi, A. Langlais, P. missy, F. Morin, F. Barlesi, D. Moro-Sibilot, J. Cadranel, M. Beau-Faller
Journal: Annals of Oncology (2017)
High Court will hear class action against metal-on-metal hip manufacturer
Authors: Clare Dyer
Journal: BMJ (2017)

More than 300 patients who had metal-on-metal hip implants will take their case to the High Court in London on 16 October in one of the biggest product liability cases to have been heard in the UK.

The trial of the group action against the US based manufacturer DePuy over its Pinnacle Ultamet implant is expected to last until the end …
Levodopa and Parkinson Disease—Myths Revisited
Authors: Shen-Yang Lim, Werner Poewe, Ai Huey Tan
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Authors: Robert Marcus, Andrew Davies, Kiyoshi Ando, Wolfram Klapper, Stephen Opat, Carolyn Owen, Elizabeth Phillips, Randeep Sangha, Rudolf Schlag, John F. Seymour, William Townsend, Marek Trněný, Michael Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann
Journal: New England Journal of Medicine (2017)

Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
GW28-e1145 The Typing and Radiofrequency Catheter Ablation of Atrioventricular Nodal Reentrant Tachycardia
Authors: Mingning Ding, Wang Zulu, Li Shibei, Liang Yanchun, Liang Ming, Yang Guitang, Jin Zhiqing, Yu Haibo, Han Yaling, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival
Authors: S. Chawla, B.A. Van Tine, S. Pollack, K. Ganjoo, A. Elias, R.F. Riedel, S. Attia, E. Choy, S. Okuno, M. Agulnik, M. von Mehren, M. Livingston, V. Keedy, C. Verschraegen, T. Philip, C. Bohac, H. Lu, M. Chen, R. Maki
Journal: Annals of Oncology (2017)
Doença de Creuzfeldt-Jakob: resultados de um inquérito feito aos 15 países membros da União Europeia
Authors: B. C. Merkel, P. W.J Peters, L Chambaud
Journal: Eurosurveillance (1996)

A doenca de Creuzfeldt-Jakob (DCJ) foi descrita pela primeira vez em 1920-1921. E uma doenca rara com uma incidencia notificada na Europa de 0,5 a 1 caso por milhao de habitantes(1). Esta demencia fatal pertence a categoria das Encefalopatias Espongiformes Transmissiveis (EET) que no homem compreendem o Sindroma de Gerstmann-Straussler-Scheinker, o kuru e a insonia fatal familiar, doencas todas elas raras. As EET constituem um grupo de doencas degenerativas subagudas do cerebro, causadas por agentes filtraveis 'nao convencionais', com periodos de incubacao muito longos e sem resposta inflamatoria ou imune demonstraveis (2). A DCJ ocorre mais frequentemente sob a forma esporadica, embora em cerca de 10% dos casos se possa encontrar uma origem genetica. A DCJ tambem foi encontrada apos transplantes ou tratamentos com hormona do crescimento obtidos de cadaveres infectados pelo agente.
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy
Authors: L. Crinò, P. Bidoli, F. Roila, E. Cortesi, M.C. Garassino, F. Cappuzzo, F. Grossi, G. Tonini, G. Sarobba, G. Pinotti, G. Numico, R. Samaritani, L. Ciuffreda, A. Frassoldati, M. Bregni, A. Santo, F.V. Piantedosi, I. Alfonso, F. De Marinis, A. Delmonte
Journal: Annals of Oncology (2017)
Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
Authors: C. Saura, E. de Azambuja, D. Hlauschek, M. Oliveira, D. Zardavas, A. Jallitsch-Halper, L. de la Pena, P. Nuciforo, A. Ballestrero, M.N. Fornier, K. Boer, E. Ciruelos, V. Valero, T.R. Wilson, T.J. Stout, J.Y. Hsu, Y. Shi, M. Piccart, M. Gnant, J. Baselga
Journal: Annals of Oncology (2017)
The sarcoma policy checklist: Focusing policy efforts on sarcoma
Authors: B. Kasper, P.G. Casali, N. Drove, S. Dumont, M. Eriksson, A. Gronchi, E. Lecointe, C. Valverde Morales, R. Wilson, S. Boldon, S. Wait, M. Wartenberg
Journal: Annals of Oncology (2017)
GW28-e0772 The enlarged size of the femoral vein is more accurate in the prognostication of patients with asymptomatic heart failure
Authors: Thach Nguyen, Nguyen Si Tuan, Hanh Nguyen Hieu Le, Luong Thanh Phuoc, Tran Ngoc Minh Chau, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2017)
The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial
Authors: J. Wang, Z-Y. Zhang, M.R. Mirza, L. Gilbert, M. Fabbro, A.V. Tinker, X. Wang, A. Redondo, J.S. Berek, L. Woelber, H.S. Pentikis, K.N. Moore, D. Lorusso, B. Benigno, S.J. Hazard, P. Follana, B.J. Rimel, U.A. Matulonis, S. Agarwal, V. Kansra
Journal: Annals of Oncology (2017)
Use of Firearms in Terrorist Attacks
Authors: Robert A. Tessler, Stephen J. Mooney, Cordelie E. Witt, Kathleen O’Connell, Jessica Jenness, Monica S. Vavilala, Frederick P. Rivara
Journal: JAMA Internal Medicine (2017)

in sensitivity analyses extending the incubation period to 72 hours (OR, 2.8; 95% CI, 1.2-6.3).Trends in other areas did not reach statistical significance, and the effect was not significant in an adjusted hospitalwide analysis.Subsequent investigation revealed that cleaning practices for the scanner table of the CT-ED had not yet been updated to match the standardized methods applied in other radiology suites.Discussion | In a large university hospital, passing through the CT-ED within 24 hours after a patient with C difficile had been there was associated with increased risk of developing CDI.Our novel analytic methods identified a previously undiscovered opportunity for real-world practice change.We continue to monitor the success of improved cleaning practices implemented as a result of this study.Leveraging EHR data for spatial and temporal analytics may be a widely applicable strategy for infection control and quality improvement at other institutions and for other infectious diseases.
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
Authors: J. Garcia-Corbacho, A. Spira, V. Boni, J. Feliu, M. Middleton, H. Burris, A. Yang Weaver, M. Will, J. Harding, F. Meric-Bernstam, V. Heinemann
Journal: Annals of Oncology (2017)
Relatório preliminar de um surto de infecção a Salmonella anatum associado a um leite maternizado
Authors: Royaume-Uni et le réseau Salm-Net
Journal: Eurosurveillance (1997)

Em Novembro e Dezembro de 1996 e inicio de Janeiro, o numero de isolamentos de Salmonella anatum em lactentes (de 1 a 11 meses) em Inglaterra e Gales foi mais elevado que o esperado. O PHLS-LEP (Public Health Laboratory Service-Laboratory of Enteric Pathogens) identificou esse aumento e iniciou a investigacao, em finais de Janeiro de 1997. Inicialmente, o PHLS-CDSC (Communicable Disease Surveillance Centre) e o SCIEH (Scotish Centre for Infection and Environmental Health) identificaram, no Reino Unido, 12 casos de infeccao a Salmonella anatum em lactentes, oito em Inglaterra e quatro na Escocia. A idade destes casos dirigiu a suspeita para a alimentacao infantil, como possivel veiculo. A base de dados da rede internacional de vigilância Salm-Net foi examinada e todos os colaboradores dos paises europeus foram inquiridos sobre casos recentes nos seus paises.
Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)
Authors: E.A. Rozeman, M.A. Deken, J. Gadiot, M.H. Geukes Foppen, L. Pronk, J.V. Thienen, J.B. Haanen, C.U. Blank
Journal: Annals of Oncology (2017)
Immune-stroma-histological (ISH)-risk score identifies low-risk group within LN-positive breast cancers
Authors: A. Grigoriadis, P. Gazinska, S. Pinder, T. Pai, S. Irshad, Y. Wu, C.E. Gillett, A.N. Tutt, A.C.C. Coolen
Journal: Annals of Oncology (2017)
Relief for Graft-vs-Host Disease
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients
Authors: T. Yokota, S. Hamauchi, Y. Yoshida, T. Yurikusa, M. Suzuki, A. Yamashita, H. Ogawa, T. Onoe, K. Mori, T. Onitsuka
Journal: Annals of Oncology (2017)